Journal article
PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma
Abstract
2011
Background: Venous thromboembolism (VTE) occurs in 20–30% of patients with malignant glioma per year of survival. We have conducted an RCT testing the efficacy and safety of long-term dalteparin for the prevention of VTE in newly diagnosed malignant glioma. Methods: Adults with newly diagnosed malignant glioma were randomized to receive dalteparin 5,000 anti-Xa units or placebo, both subcutaneously daily for 6 months …
Authors
Perry JR; Rogers L; Laperriere N; Julian J; Geerts W; Agnelli G; Malkin M; Sawaya R; Baker R; Levine M
Journal
Journal of Clinical Oncology, Vol. 25, No. 18_suppl, pp. 2011–2011
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2007
DOI
10.1200/jco.2007.25.18_suppl.2011
ISSN
0732-183X